Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial.

Acute Coronary Syndrome / drug therapy Drug Therapy, Combination Female Follow-Up Studies Hemorrhage / chemically induced Humans Male Percutaneous Coronary Intervention Platelet Aggregation Inhibitors / therapeutic use Prospective Studies Sex Factors Stents Stroke Thrombosis Treatment Outcome

ACS Bleeding DAPT duration Gender Mortality PCI Thrombosis

Journal

Journal of thrombosis and thrombolysis

ISSN: 1573-742X

Titre abrégé: J Thromb Thrombolysis

Pays: Netherlands

ID NLM: 9502018

Informations de publication

Date de publication:
Oct 2021

Historique:

accepted: 26 03 2021

pubmed: 14 4 2021

medline: 1 3 2022

entrez: 13 4 2021

Statut: ppublish

Résumé

Gender differences in the thrombotic and bleeding risk have been suggested to condition the benefits of antithrombotic therapies in Acute Coronary Syndrome (ACS) patients, and mainly among those undergoing percutaneous coronary interventions with drug eluting stents (DES). The impact of gender on the optimal duration of dual antiplatelet therapy (DAPT) in ACS patients is still unexplored and was, therefore, the aim of the present sub-study. REDUCE was a prospective, multicenter, randomized investigator-initiated study designed to enroll 1500 ACS patients after treatment with the COMBO Dual Stent Therapy, based on a noninferiority design. Patients were randomized in a 1:1 fashion to either 3 or 12 months of DAPT. Primary study endpoint was a composite of all-cause mortality, myocardial infarction, definite/probable stent thrombosis (ST), stroke, target-vessel revascularization (TVR) and bleedings (BARC II, III, V) at 12 months. Secondary endpoints were cardiovascular mortality and the individual components of the primary endpoint within 24 months. From June 2014 to May 2016 300 women and 1196 men were included in the study. Among them, 43.7% of females and 51.9% of males were assigned to the 3 months DAPT treatment. Baseline characteristics were well matched between the two arms, with the exception of a lower rate of TIMI flow < 3 (p = 0.04), lower systolic blood pressure (p = 0.05) and use of spironolactone (p = 0.006) among women and a more advanced age (p = 0.05) among men receiving a short-term DAPT. At a mean follow-up of 525 (± 198) days, no difference in the primary endpoint was observed according to DAPT duration in both females [6.9% vs 5.9%, HR (95% CI) = 1.19 (0.48-2.9), p = 0.71] and males [8.2% vs 9%, HR (95% CI) = 0.92 (0.63-1.35), p = 0.67; p INT = 0.20]. Results were confirmed after correction for baseline differences [females: adjusted HR (95% CI) = 1.12 (0.45-2.78), p = 0.81; males: adjusted HR (95% CI) = 0.90 (0.61-1.32), p = 0.60]. Comparable rates of survival, thrombotic (MI, stent thrombosis, TVR, stroke) and bleeding events were observed with the two DAPT strategies, with no impact of gender. The present study shows that among ACS patients randomized in the REDUCE trial, a 3 months DAPT strategy offers comparable results as compared to a standard 12 months DAPT at 2-years follow-up in both male and female gender.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

REDUCE was a prospective, multicenter, randomized investigator-initiated study designed to enroll 1500 ACS patients after treatment with the COMBO Dual Stent Therapy, based on a noninferiority design. Patients were randomized in a 1:1 fashion to either 3 or 12 months of DAPT. Primary study endpoint was a composite of all-cause mortality, myocardial infarction, definite/probable stent thrombosis (ST), stroke, target-vessel revascularization (TVR) and bleedings (BARC II, III, V) at 12 months. Secondary endpoints were cardiovascular mortality and the individual components of the primary endpoint within 24 months.

RESULTS RESULTS

From June 2014 to May 2016 300 women and 1196 men were included in the study. Among them, 43.7% of females and 51.9% of males were assigned to the 3 months DAPT treatment. Baseline characteristics were well matched between the two arms, with the exception of a lower rate of TIMI flow < 3 (p = 0.04), lower systolic blood pressure (p = 0.05) and use of spironolactone (p = 0.006) among women and a more advanced age (p = 0.05) among men receiving a short-term DAPT. At a mean follow-up of 525 (± 198) days, no difference in the primary endpoint was observed according to DAPT duration in both females [6.9% vs 5.9%, HR (95% CI) = 1.19 (0.48-2.9), p = 0.71] and males [8.2% vs 9%, HR (95% CI) = 0.92 (0.63-1.35), p = 0.67; p INT = 0.20]. Results were confirmed after correction for baseline differences [females: adjusted HR (95% CI) = 1.12 (0.45-2.78), p = 0.81; males: adjusted HR (95% CI) = 0.90 (0.61-1.32), p = 0.60]. Comparable rates of survival, thrombotic (MI, stent thrombosis, TVR, stroke) and bleeding events were observed with the two DAPT strategies, with no impact of gender.

CONCLUSIONS CONCLUSIONS

The present study shows that among ACS patients randomized in the REDUCE trial, a 3 months DAPT strategy offers comparable results as compared to a standard 12 months DAPT at 2-years follow-up in both male and female gender.

Identifiants

DOI: 10.1007/s11239-021-02439-x PMID: 33847862

pubmed: 33847862

doi: 10.1007/s11239-021-02439-x

pii: 10.1007/s11239-021-02439-x

doi:

Substances chimiques

Platelet Aggregation Inhibitors 0

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

Pagination

797-807

Informations de copyright

Références

Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS) (2015) Impact of gender difference on vitamin D status and its relationship with the extent of coronary artery disease. Nutr Metab Cardiovasc Dis 25(5):464–470

pubmed: 25791862 doi: 10.1016/j.numecd.2015.01.009

Barbieri L, Verdoia M, Schaffer A, Marino P, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS) (2015) Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: a single-centre study. Atherosclerosis 241(1):241

pubmed: 25818387 doi: 10.1016/j.atherosclerosis.2015.03.030

Barbieri L, Verdoia M, Nardin M, Marino P, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS) (2017) Gender difference in the risk of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous coronary intervention. Angiology 68(6):542–546

pubmed: 27662891 doi: 10.1177/0003319716669429

Cenko E, Yoon J, Kedev S, Stankovic G, Vasiljevic Z, Krljanac G, Kalpak O, Ricci B, Milicic D, Manfrini O, van der Schaar M, Badimon L, Bugiardini R (2018) Sex differences in outcomes after STEMI: effect modification by treatment strategy and age. JAMA Intern Med 178(5):632–639

pubmed: 29630703 pmcid: 6145795 doi: 10.1001/jamainternmed.2018.0514

De Luca G, Gibson CM, Gyöngyösi M, Zeymer U, Dudek D, Arntz HR, Bellandi F, Maioli M, Noc M, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Huber K, van’t Hof AW (2010) Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. J Thromb Thrombolysis 30(3):342–346. https://doi.org/10.1007/s11239-010-0451-y

doi: 10.1007/s11239-010-0451-y pubmed: 20213259

De Luca G, Verdoia M, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, Hoeven BV, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, de la Llera LSD, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, Stone GW, DESERT Cooperation (2013) Gender-related differences in outcome after BMS or DES implantation in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: insights from the DESERT cooperation. Atherosclerosis 230(1):12–16

pubmed: 23958246 doi: 10.1016/j.atherosclerosis.2013.05.024

De Luca G, Biondi-Zoccai G, Marino P (2008) Transferring patients with ST-segment elevation myocardial infarction for mechanical reperfusion: a meta-regression analysis of randomized trials. Ann Emerg Med 52(6):665–676

pubmed: 19027496 doi: 10.1016/j.annemergmed.2008.08.033

De Luca G, Smits P, Hofma SH, Di Lorenzo E, Vlachojannis GJ, Van’t Hof AWJ, van Boven AJ, Kedhi E, Stone GW, Suryapranata H, Drug-Eluting Stent in Primary Angioplasty (DESERT 3) cooperation (2017) Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Int J Cardiol 244:121–127

pubmed: 28673736 doi: 10.1016/j.ijcard.2017.06.022

De Luca G, Navarese EP, Suryapranata H (2013) A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol 166:606–612

pubmed: 22284272 doi: 10.1016/j.ijcard.2011.11.102

De Luca G, Smit JJ, Ernst N, Suryapranata H, Ottervanger JP, Hoorntje JC, Dambrink JH, Gosslink AT, de Boer MJ, van’t Hof AW (2005) Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 93(5):820–823

pubmed: 15886794 doi: 10.1160/TH04-11-0726

Landes U, Kornowski R, Assali A, Vaknin-Assa H, Greenberg G, Lev EI, Bental T (2015) Predictors of long term outcomes in 11441 consecutive patients following percutaneous coronary interventions. Am J Cardiol. https://doi.org/10.1016/j.amjcard.2015.01.009 (Epub ahead of print)

doi: 10.1016/j.amjcard.2015.01.009 pubmed: 25678393

Pancholy SB, Shantha GP, Patel T, Cheskin LJ (2014) Sex differences in short-term and long-term all-cause mortality among patients with ST-segment elevation myocardial infarction treated by primary percutaneous intervention: a meta-analysis. JAMA Intern Med 174:1822–1830

pubmed: 25265319 doi: 10.1001/jamainternmed.2014.4762

De Luca G, Parodi G, Sciagrà R, Bellandi B, Verdoia M, Vergara R, Migliorini A, Valenti R, Antoniucci D (2013) Relation of gender to infarct size in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty. Am J Cardiol 111(7):936–940

pubmed: 23332594 doi: 10.1016/j.amjcard.2012.12.011

De Luca G, Suryapranata H, Dambrink JH, Ottervanger JP, van’t Hof AW, Zijlstra F, Hoorntje JC, Gosselink AT, de Boer MJ (2004) Sex-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty: data from the Zwolle Myocardial Infarction study. Am Heart J 148:852–856

pubmed: 15523317 doi: 10.1016/j.ahj.2004.05.018

De Luca G, van’t Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, Zijlstra F, de Boer MJ, Suryapranata H (2005) Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Am Heart J 150(3):557–562

pubmed: 16169340 doi: 10.1016/j.ahj.2004.10.044

Mohamed MO, Rashid M, Timmis A, Clarke S, Lawson C, Michos ED, Kwok CS, De Belder M, Valgimigli M, Mamas MA (2020) Sex differences in distribution, management and outcomes of combined ischemic-bleeding risk following acute coronary syndrome. Int J Cardiol S0167–5273(20):34311–34314

Khan E, Brieger D, Amerena J, Atherton JJ, Chew DP, Farshid A, Ilton M, Juergens CP, Kangaharan N, Rajaratnam R, Sweeny A, Walters DL, Chow CK (2018) Differences in management and outcomes for men and women with ST-elevation myocardial infarction. Med J Aust 209(3):118–123

pubmed: 30025513 doi: 10.5694/mja17.01109

D’Ascenzo F, Colombo F, Barbero U, Moretti C, Omedè P, Reed MJ, Tarantini G, Frati G, Di Nicolantonio JJ, Biondi Zoccai G, Gaita F (2014) Discontinuation of dual antiplatelet therapy over 12 months after acute coronary syndromes increases risk for adverse events in patients treated with percutaneous coronary intervention: systematic review and meta-analysis. J Interv Cardiol 27(3):233–241

pubmed: 24627967 doi: 10.1111/joic.12107

Haude M, Lee SW, Worthley SG et al (2013) The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. JACC cardiovasc interv 6:334–343

pubmed: 23523459 doi: 10.1016/j.jcin.2012.10.018

Palmerini T, Della Riva D, Benedetto U et al (2017) Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11473 patients. Eur Heart J 38:1034–1043

pubmed: 28110296 pmcid: 5837418

Verdoia M, Kedhi E, Ceccon C, Suryapranata H, De Luca G (2018) Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: a meta-analysis of 11 randomized trials. Int J Cardiol 264:30–38

pubmed: 29776573 doi: 10.1016/j.ijcard.2018.02.095

Nakazawa G, Granada JF, Alviar CL et al (2010) Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv 3:68–75

pubmed: 20129572 doi: 10.1016/j.jcin.2009.09.015

Räber L, Zanchin T, Baumgartner S et al (2014) Differential healing response attributed to culprit lesions of patients with acute coronary syndromes and stable coronary artery after implantation of drug-eluting stents: an optical coherence tomography study. Int J Cardiol 173:259–267

pubmed: 24631113 doi: 10.1016/j.ijcard.2014.02.036

De Luca G, Damen SA, Camaro C, Benit E, Verdoia M, Rasoul S, Liew HB, Polad J, Ahmad WA, Zambahari R, Postma S, Kedhi E, Suryapranata H, Collaborators (2019) Final results of the Randomised Evaluation of short-term DUal antiplatelet therapy in patients with acute Coronary syndromE treated with a new generation stent (REDUCE) trial. EuroIntervention. https://doi.org/10.4244/EIJ-D-19-00539 (Epub ahead of print)

doi: 10.4244/EIJ-D-19-00539 pubmed: 31422929

Thygesen K, Alpert JS, Jaffe AS et al (2012) Joint ESC/ACCF/AHA/WHF task force for the universal definition of myocardial infarction. Third universal definition of myocardial infarction. Circulation 126:2020–2035

pubmed: 22923432 doi: 10.1161/CIR.0b013e31826e1058

Cutlip DE, Windecker S, Mehran R, Academic Research Consortium et al (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351

pubmed: 17470709 doi: 10.1161/CIRCULATIONAHA.106.685313

Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:2736–2747

pubmed: 21670242 pmcid: 21670242 doi: 10.1161/CIRCULATIONAHA.110.009449

Camaro C, Damen SA, Brouwer MA et al (2016) Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. Am Heart J 178:37–44

pubmed: 27502850 doi: 10.1016/j.ahj.2016.04.016

Verdoia M, Schaffer A, Barbieri L, Montalescot G, Collet JP, Colombo A, Suryapranata H, De Luca G (2016) Optimal duration of dual antiplatelet therapy after DES implantation: a meta-analysis of 11 randomized trials. Angiology 67(3):224–238

pubmed: 26069031 doi: 10.1177/0003319715586500

Mauri L, Kereiakes DJ, Yeh RW et al (2014) Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155–2166

pubmed: 25399658 pmcid: 4481318 doi: 10.1056/NEJMoa1409312

Bonaca MP, Bhatt DL, Cohen M, PEGASUS-TIMI 54 Steering Committee and Investigators (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791–1800

pubmed: 25773268 doi: 10.1056/NEJMoa1500857

Didier R, Morice MC, Barragan P et al (2017) 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: final results of the ITALIC trial (is there a life for des after discontinuation of clopidogrel). JACC Cardiovasc Interv 10:1202–1210

pubmed: 28641840 doi: 10.1016/j.jcin.2017.03.049

Verdoia M, Schaffer A, Barbieri L et al (2014) Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials. J Cardiovasc Pharmacol 63:339–350

pubmed: 24336016 doi: 10.1097/FJC.0000000000000052

Palmerini T, Reggiani LB, Riva DD et al (2017) Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting. J Am Coll Cardiol 69:2011–2022

pubmed: 28427576 doi: 10.1016/j.jacc.2017.02.029

Benenati S, Crimi G, Canale C, Pescetelli F, De Marzo V, Vergallo R, Galli M, Della Bona R, Canepa M, Ameri P, Crea F, Porto I (2020) Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug eluting stent implantation: a network meta-analysis. Eur Heart J Cardiovasc Pharmacother. https://doi.org/10.1093/ehjcvp/pvaa127

doi: 10.1093/ehjcvp/pvaa127 pubmed: 33135064

Benenati S, Galli M, De Marzo V, Pescetelli F, Toma M, Andreotti F, Bona RD, Canepa M, Ameri P, Crea F, Porto I (2020) Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Pharmacother. https://doi.org/10.1093/ehjcvp/pvaa001

doi: 10.1093/ehjcvp/pvaa001 pubmed: 33135064

Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Kirtane AJ, Stone GW, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S (2016) Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol 67(19):2224–2234

pubmed: 27079334 doi: 10.1016/j.jacc.2016.02.064

Gutiérrez-Chico JL, Mehilli J (2013) Gender differences in cardiovascular therapy: focus on antithrombotic therapy and percutaneous coronary intervention. Drugs 73(17):1921–1933

pubmed: 24155117 doi: 10.1007/s40265-013-0135-y

Russ MA, Wackerl C, Zeymer U, Hochadel M, Kerber S, Zahn R, Zrenner B, Topp H, Schächinger V, Weber MA, ALKK-Study Group (2017) Gender based differences in drug eluting stent implantation—data from the German ALKK registry suggest underuse of DES in elderly women. BMC Cardiovasc Disord 17(1):68

pubmed: 28241861 pmcid: 5327567 doi: 10.1186/s12872-017-0500-y

Alabas OA, Gale CP, Hall M, Rutherford MJ, Szummer K, Lawesson SS, Alfredsson J, Lindahl B, Jernberg T (2017) Sex differences in treatments, relative survival, and excess mortality following acute myocardial infarction: national cohort study using the SWEDEHEART registry. J Am Heart Assoc 61:2

Josiah A, Farshid A (2018) Gender is not a predictor of mortality or major adverse cardiovascular events in patients undergoing percutaneous coronary intervention for acute coronary syndromes. Heart Lung Circ. https://doi.org/10.1016/j.hlc.2018.03.020

doi: 10.1016/j.hlc.2018.03.020 pubmed: 29705386

Numasawa Y, Inohara T, Ishii H, Kuno T, Kodaira M, Kohsaka S, Fujii K, Uemura S, Amano T, Kadota K, Nakamura M (2017) Comparison of outcomes of women versus men with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the Japanese nationwide registry). Am J Cardiol 119(6):826–831

pubmed: 28040190 doi: 10.1016/j.amjcard.2016.11.034

Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M, Himmelmann A, Horrow J, Katus HA, Lassila R, Morais J, Nicolau JC, Steg PG, Storey RF, Wojdyla D, Wallentin L, PLATO study group (2014) The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 35(23):1541–1550

pubmed: 24682844 pmcid: 4057642 doi: 10.1093/eurheartj/ehu075

Wiviott SD, Braunwald E, McCabe CH, TRITON-TIMI 38Investigators et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015

pubmed: 17982182 doi: 10.1056/NEJMoa0706482

Yu J, Mehran R, Baber U, Ooi SY, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Brodie BR, Stuckey TD, Maehara A, Xu K, Ben-Yehuda O, Kirtane AJ, Stone GW (2017) Sex differences in the clinical impact of high platelet reactivity after percutaneous coronary intervention with drug-eluting stents: results from the ADAPT-DES study (assessment of dual antiplatelet therapy with drug-eluting stents). Circ Cardiovasc Interv. https://doi.org/10.1161/CIRCINTERVENTIONS.116.003577

doi: 10.1161/CIRCINTERVENTIONS.116.003577 pubmed: 29246916

Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Daffara V, Marino P, Bellomo G, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS) (2016) Gender differences in platelet reactivity in patients receiving dual antiplatelet therapy. Cardiovasc Drugs Ther 30(2):143–150

pubmed: 26868495 doi: 10.1007/s10557-016-6646-5

Giustino G, Redfors B, Mehran R, Kirtane AJ, Baber U, Généreux P, Witzenbichler B, Neumann FJ, Weisz G, Maehara A, Rinaldi MJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Brodie BR, Stuckey TD, Dangas GD, Brener SJ, Ozgu Ozan M, Stone GW (2017) Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: from the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. Int J Cardiol 246:20–25

pubmed: 28867009 doi: 10.1016/j.ijcard.2017.05.091

Mehta SR, Yusuf S, Peters RJ, Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533

pubmed: 11520521 doi: 10.1016/S0140-6736(01)05701-4